右美托咪定对主动脉共济失调修复术后高血压发生率的影响

Q2 Medicine

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-04-01 Epub Date: 2024-04-08 DOI:10.5863/1551-6776-29.2.144

Hope Mae L Abarintos, Christine A Kapuscinski, Taylor Wheaton, Sierra D Stauber, Michael F Swartz, Madeline Grossman, Sarah Masri, David J Hutchinson

{"title":"右美托咪定对主动脉共济失调修复术后高血压发生率的影响","authors":"Hope Mae L Abarintos, Christine A Kapuscinski, Taylor Wheaton, Sierra D Stauber, Michael F Swartz, Madeline Grossman, Sarah Masri, David J Hutchinson","doi":"10.5863/1551-6776-29.2.144","DOIUrl":null,"url":null,"abstract":"Objective: Recent literature suggests a potential role for dexmedetomidine in reducing the incidence and severity of hypertension following repair of coarctation of the aorta (CoA). The primary aim of this study was to assess the association between dexmedetomidine use and the incidence of hypertension following repair of CoA in pediatric patients.Methods: This was a single-center, retrospective cohort study in patients younger than 19 years who underwent surgical repair of CoA between January 1, 2016, and September 30, 2021. Patients were divided into 2 groups: dexmedetomidine initiation within the first 3 hours after surgery or no dexmedetomidine. The primary outcome was incidence of hypertension within the first 4 to 24 hours after repair. Secondary outcomes included the incidence of hypotension and bradycardia.Results: A total of 80 patients were included, 25 (31.25%) received dexmedetomidine. Median age at the time of procedure was 26 days (IQR, 13-241) in the dexmedetomidine group and 14 days (IQR, 8-53) in the no dexmedetomidine group (p = 0.014). The primary outcome of hypertension was met in 7 patients (28%) in the dexmedetomidine group and 12 patients (21.8%) in the no dexmedetomidine group, p = 0.547. The only variable found to be associated with the incidence of hypertension was age greater than 30 days at the time of procedure. More patients who received dexmedetomidine experienced bradycardia. There was no difference in the incidence of hypotension.Conclusions: There was no association between the use of dexmedetomidine and the incidence of -hypertension following repair of CoA in pediatric patients.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001214/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of Dexmedetomidine on Incidence of Hypertension Following Repair of Coarctation of the Aorta.\",\"authors\":\"Hope Mae L Abarintos, Christine A Kapuscinski, Taylor Wheaton, Sierra D Stauber, Michael F Swartz, Madeline Grossman, Sarah Masri, David J Hutchinson\",\"doi\":\"10.5863/1551-6776-29.2.144\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Recent literature suggests a potential role for dexmedetomidine in reducing the incidence and severity of hypertension following repair of coarctation of the aorta (CoA). The primary aim of this study was to assess the association between dexmedetomidine use and the incidence of hypertension following repair of CoA in pediatric patients.Methods: This was a single-center, retrospective cohort study in patients younger than 19 years who underwent surgical repair of CoA between January 1, 2016, and September 30, 2021. Patients were divided into 2 groups: dexmedetomidine initiation within the first 3 hours after surgery or no dexmedetomidine. The primary outcome was incidence of hypertension within the first 4 to 24 hours after repair. Secondary outcomes included the incidence of hypotension and bradycardia.Results: A total of 80 patients were included, 25 (31.25%) received dexmedetomidine. Median age at the time of procedure was 26 days (IQR, 13-241) in the dexmedetomidine group and 14 days (IQR, 8-53) in the no dexmedetomidine group (p = 0.014). The primary outcome of hypertension was met in 7 patients (28%) in the dexmedetomidine group and 12 patients (21.8%) in the no dexmedetomidine group, p = 0.547. The only variable found to be associated with the incidence of hypertension was age greater than 30 days at the time of procedure. More patients who received dexmedetomidine experienced bradycardia. There was no difference in the incidence of hypotension.Conclusions: There was no association between the use of dexmedetomidine and the incidence of -hypertension following repair of CoA in pediatric patients.\",\"PeriodicalId\":37484,\"journal\":{\"name\":\"Journal of Pediatric Pharmacology and Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001214/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Pharmacology and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5863/1551-6776-29.2.144\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5863/1551-6776-29.2.144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的：最近的文献表明，右美托咪定在降低主动脉共动脉症（CoA）修复术后高血压的发生率和严重程度方面具有潜在作用。本研究的主要目的是评估右美托咪定的使用与儿科患者CoA修复术后高血压发病率之间的关系：这是一项单中心、回顾性队列研究，对象是在2016年1月1日至2021年9月30日期间接受CoA手术修复的19岁以下患者。患者分为两组：术后3小时内开始使用右美托咪定或不使用右美托咪定。主要结果是手术后 4-24 小时内的高血压发生率。次要结果包括低血压和心动过缓的发生率：共纳入80名患者，其中25人（31.25%）使用了右美托咪定。右美托咪定组患者手术时的中位年龄为 26 天（IQR，13-241），无右美托咪定组患者手术时的中位年龄为 14 天（IQR，8-53）（P = 0.014）。右美托咪定组有 7 名患者（28%）达到了高血压的主要结果，无右美托咪定组有 12 名患者（21.8%）达到了高血压的主要结果，p = 0.547。发现与高血压发病率相关的唯一变量是手术时年龄大于 30 天。更多使用右美托咪定的患者出现心动过缓。低血压的发生率没有差异：结论：使用右美托咪定与儿科患者CoA修复术后高血压的发生率没有关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effect of Dexmedetomidine on Incidence of Hypertension Following Repair of Coarctation of the Aorta.

Objective: Recent literature suggests a potential role for dexmedetomidine in reducing the incidence and severity of hypertension following repair of coarctation of the aorta (CoA). The primary aim of this study was to assess the association between dexmedetomidine use and the incidence of hypertension following repair of CoA in pediatric patients.

Methods: This was a single-center, retrospective cohort study in patients younger than 19 years who underwent surgical repair of CoA between January 1, 2016, and September 30, 2021. Patients were divided into 2 groups: dexmedetomidine initiation within the first 3 hours after surgery or no dexmedetomidine. The primary outcome was incidence of hypertension within the first 4 to 24 hours after repair. Secondary outcomes included the incidence of hypotension and bradycardia.

Results: A total of 80 patients were included, 25 (31.25%) received dexmedetomidine. Median age at the time of procedure was 26 days (IQR, 13-241) in the dexmedetomidine group and 14 days (IQR, 8-53) in the no dexmedetomidine group (p = 0.014). The primary outcome of hypertension was met in 7 patients (28%) in the dexmedetomidine group and 12 patients (21.8%) in the no dexmedetomidine group, p = 0.547. The only variable found to be associated with the incidence of hypertension was age greater than 30 days at the time of procedure. More patients who received dexmedetomidine experienced bradycardia. There was no difference in the incidence of hypotension.

Conclusions: There was no association between the use of dexmedetomidine and the incidence of -hypertension following repair of CoA in pediatric patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pediatric Pharmacology and Therapeutics Medicine-Pediatrics, Perinatology and Child Health

CiteScore

2.40

自引率

0.00%

发文量

期刊介绍： The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy. The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues. The Journal will contain original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.